Navidea Biopharmaceuticals, Inc. and MacRophage Therapeutics, Inc. v. Capital Royalty Partners II, L.P., Capital Royalty Partners II - Parallel Fund "A", L.P., Parallel Investment Opportunities Partners, II, L.P., Capital Royalty Partners II (Cayman) L.P., CR Group, L.P., CRG Servicing, LLC, and Capital Royalty Partners II – Parallel Fund "B" (Cayman) L.P.

Motion Granted; Appeal Dismissed and Memorandum Opinion filed
December 28, 2023

In The

Fourteenth Court of Appeals

NO. 14-22-00882-CV

NAVIDEA BIOPHARMACEUTICALS, INC. AND MACROPHAGE
THERAPEUTICS, INC., Appellants

V.

CAPITAL ROYALTY PARTNERS II, L.P.; CAPITAL ROYALTY
PARTNERS II - PARALLEL FUND “A”, L.P.; PARALLEL INVESTMENT
OPPORTUNITIES PARTNERS, II, L.P.; CAPITAL ROYALTY
PARTNERS II (CAYMAN) L.P.; CR GROUP, L.P.; CRG SERVICING,
LLC; AND CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “B”
(CAYMAN) L.P., Appellees

On Appeal from the 151st District Court
Harris County, Texas
Trial Court Cause No. 2018-24442

MEMORANDUM OPINION
This is an appeal from a judgment signed September 1, 2022. On December
6, 2023, appellants filed an agreed motion to dismiss the appeal. See Tex. R. App.
P. 42.1. The motion is granted. Costs are taxed against the party incurring such
costs.

We dismiss the appeal.

PER CURIAM

Panel consists of Justices Bourliot, Zimmerer and Spain.

2